The universal vaccine for the treatment and prophylaxis of Lyme disease for human and veterinary use, based on whole-cell bacterins or bacterial lysates or purificates of at least one or more borrelia genomospecies, which essence lies in the fact that each borrelia genomospecies, selected preferably from the group of Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii, contains as a minimum one immunogenic protective protein of outer membrane, either OspA or OspC, or simultaneously both the immunogenic protective proteins OspA and OspC, or possibly other immunogenic protective proteins of outer membrane.